Paratek Pharmaceuticals (NASDAQ:PRTK) received a $50.00 price target from research analysts at Cantor Fitzgerald in a report issued on Monday, June 11th. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 369.48% from the stock’s current price.
PRTK has been the subject of several other research reports. HC Wainwright increased their price objective on Paratek Pharmaceuticals from $43.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, March 2nd. Zacks Investment Research lowered Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. UBS Group lowered Paratek Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research note on Friday, March 2nd. BidaskClub lowered Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 24th. Finally, Leerink Swann reaffirmed an “outperform” rating on shares of Paratek Pharmaceuticals in a research note on Sunday, March 4th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $40.00.
Shares of PRTK opened at $10.65 on Monday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 8.06 and a current ratio of 8.06. The stock has a market capitalization of $338.08 million, a P/E ratio of -3.23 and a beta of 0.55. Paratek Pharmaceuticals has a 12-month low of $9.85 and a 12-month high of $29.00.
In other Paratek Pharmaceuticals news, Chairman Michael Bigham sold 8,700 shares of the business’s stock in a transaction on Monday, April 9th. The stock was sold at an average price of $12.70, for a total transaction of $110,490.00. Following the completion of the transaction, the chairman now owns 199,730 shares in the company, valued at approximately $2,536,571. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Adam Woodrow sold 5,700 shares of the business’s stock in a transaction on Monday, April 9th. The stock was sold at an average price of $12.70, for a total value of $72,390.00. Following the completion of the sale, the vice president now directly owns 89,167 shares in the company, valued at approximately $1,132,420.90. The disclosure for this sale can be found here. Insiders sold a total of 27,721 shares of company stock valued at $352,057 over the last quarter. Company insiders own 6.20% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. LPL Financial LLC grew its stake in Paratek Pharmaceuticals by 13.0% in the fourth quarter. LPL Financial LLC now owns 44,575 shares of the specialty pharmaceutical company’s stock valued at $798,000 after purchasing an additional 5,125 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Paratek Pharmaceuticals by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 200,782 shares of the specialty pharmaceutical company’s stock worth $3,593,000 after acquiring an additional 5,151 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Paratek Pharmaceuticals by 42.0% during the 1st quarter. Wells Fargo & Company MN now owns 27,498 shares of the specialty pharmaceutical company’s stock worth $357,000 after acquiring an additional 8,140 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Paratek Pharmaceuticals by 12.4% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 92,366 shares of the specialty pharmaceutical company’s stock worth $1,654,000 after acquiring an additional 10,202 shares in the last quarter. Finally, MetLife Investment Advisors LLC bought a new stake in Paratek Pharmaceuticals during the 4th quarter valued at approximately $185,000. 77.25% of the stock is currently owned by institutional investors.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.